Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, ...
Edgewise Therapeutics is a leading muscle-focused biopharmaceutical company dedicated to creating novel small-molecule therapies for severe musculoskeletal and cardiac diseases. The company’s core pipeline includes its lead candidate EDG-5506, an orally administered investigational drug designed to treat dystrophinopathies like Duchenne and Becker muscular dystrophy by targeting fundamental genetic defects. EDG-5506 ...Edgewise Therapeutics is a leading muscle-focused biopharmaceutical company dedicated to creating novel small-molecule therapies for severe musculoskeletal and cardiac diseases. The company’s core pipeline includes its lead candidate EDG-5506, an orally administered investigational drug designed to treat dystrophinopathies like Duchenne and Becker muscular dystrophy by targeting fundamental genetic defects. EDG-5506 has completed Phase 1 trials, and the company is advancing it through clinical development. Beyond this, Edgewise maintains a pipeline of precision medicines aimed at modulating key muscle proteins to address various genetically defined muscle conditions. Established in 2017 by Alan Russell, Peter Thompson, and Badreddin Edris, the company is headquartered in Boulder, Colorado, and trades on NASDAQ under the symbol EWTX. As of the latest data, Edgewise employs 146 full-time staff and is led by CEO Kevin Koch, Ph.D., who has deep experience in drug discovery. Financially, the company is in a strong position with a market cap of approximately $4.7 billion as of the report date, and it has a robust balance sheet with $442 million in working capital and a current ratio of 16.2. Though it currently has no revenue, it has significant cash reserves (about $4.3 per share) to support its R&D activities. Key financial metrics indicate a focus on long-term growth, with investments in research and development exceeding $160 million annually. The company’s vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company. It has a strong pipeline, an experienced leadership team, and a clear strategic focus on muscle biology, positioning it for potential success in the biotech sector.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-167.8M
-25.4%
-17.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-143.8M
-30.3%
-1.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.8%
-25.9%
+4.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
19.85x
-0.4%
-28.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
